Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +43.91%
#3 Pons Pons +21.40%
#4 ADO Protocol ADO Protocol +18.01%
#5 Main Street Yield Main Street Yield +17.48%
#6 Collect on Fanable Collect on Fanable +16.09%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.52%
#8 o1.exchange o1.exchange +13.32%
#9 Velvet Velvet +12.38%
#10 Ontology Gas Ontology Gas +12.35%
Coin of the day
GEKKO GEKKO
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Classifica tra le azioni #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Prezzo delle azioni
$9.60
Ultima sincronizzazione: 2025-05-21
Capitalizzazione di mercato
$1.08B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia OptiNose, Inc. (OPTN)

Categoria

Healthcare
Ricavi di OptiNose, Inc. (OPTN)
Ricavi nel Mar 2025 TTM: $81.86M
Secondo gli ultimi rapporti finanziari di OptiNose, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $81.86M. Nel 2023, l'azienda ha registrato ricavi di $70.99M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $76.28M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per OptiNose, Inc. da 2015 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $81.86M 4.64%
2024 $78.23M 10.20%
2023 $70.99M -6.93%
2022 $76.28M 2.18%
2021 $74.65M 51.99%
2020 $49.12M 41.83%
2019 $34.63M 390.18%
2018 $7.07M 0.00%
2017 0.00 -100.00%
2016 $47.50M 55,782.35%
2015 $85.00K 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B 7,977.17%
IN